Sandu Pharmaceuticals Ltd
Incorporated in 1985, Sandu Pharmaceuticals
Ltd is a manufacturer of Ayurvedic Medicines.[1]
- Market Cap ₹ 37.4 Cr.
- Current Price ₹ 38.7
- High / Low ₹ 58.8 / 30.0
- Stock P/E 21.1
- Book Value ₹ 45.2
- Dividend Yield 2.07 %
- ROCE 6.41 %
- ROE 4.13 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 0.86 times its book value
- Company's working capital requirements have reduced from 53.8 days to 42.0 days
Cons
- The company has delivered a poor sales growth of 3.54% over past five years.
- Promoter holding is low: 37.8%
- Company has a low return on equity of 3.85% over last 3 years.
- Promoter holding has decreased over last 3 years: -14.6%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 38.17 | 38.86 | 42.82 | 49.02 | 49.42 | 48.37 | 58.76 | 65.50 | 65.35 | 67.28 | 67.19 | 69.93 | |
| 35.74 | 35.97 | 40.97 | 46.55 | 47.33 | 46.92 | 56.60 | 62.62 | 62.86 | 64.98 | 64.43 | 66.93 | |
| Operating Profit | 2.43 | 2.89 | 1.85 | 2.47 | 2.09 | 1.45 | 2.16 | 2.88 | 2.49 | 2.30 | 2.76 | 3.00 |
| OPM % | 6.37% | 7.44% | 4.32% | 5.04% | 4.23% | 3.00% | 3.68% | 4.40% | 3.81% | 3.42% | 4.11% | 4.29% |
| 0.14 | 0.12 | 0.56 | 0.12 | 0.57 | 0.45 | 0.19 | 0.08 | 0.33 | 0.42 | 0.17 | 0.44 | |
| Interest | 1.37 | 1.64 | 1.49 | 1.23 | 1.01 | 0.43 | 0.11 | 0.11 | 0.08 | 0.06 | 0.10 | 0.11 |
| Depreciation | 0.57 | 0.69 | 0.87 | 0.60 | 0.64 | 0.55 | 0.56 | 0.53 | 0.52 | 0.58 | 0.67 | 0.68 |
| Profit before tax | 0.63 | 0.68 | 0.05 | 0.76 | 1.01 | 0.92 | 1.68 | 2.32 | 2.22 | 2.08 | 2.16 | 2.65 |
| Tax % | 34.92% | 22.06% | 1,000.00% | 26.32% | 34.65% | 21.74% | 35.12% | 31.47% | 31.08% | 29.33% | 28.24% | 33.58% |
| 0.41 | 0.54 | -0.44 | 0.56 | 0.67 | 0.72 | 1.09 | 1.59 | 1.52 | 1.46 | 1.55 | 1.77 | |
| EPS in Rs | 0.58 | 0.76 | -0.62 | 0.79 | 0.95 | 1.02 | 1.38 | 1.80 | 1.57 | 1.51 | 1.60 | 1.83 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 36.33% | 41.56% | 0.00% | 52.93% | 49.86% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 4% |
| 3 Years: | 2% |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 10% |
| 3 Years: | 5% |
| TTM: | 14% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | -1% |
| 3 Years: | -12% |
| 1 Year: | -31% |
| Return on Equity | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 4% |
| 3 Years: | 4% |
| Last Year: | 4% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7.08 | 7.08 | 7.08 | 7.08 | 7.08 | 7.08 | 7.92 | 8.81 | 9.66 | 9.66 | 9.66 | 9.66 |
| Reserves | 11.06 | 11.60 | 20.33 | 21.00 | 21.71 | 22.16 | 25.57 | 27.66 | 29.58 | 30.93 | 32.36 | 34.01 |
| 12.47 | 11.39 | 10.56 | 9.42 | 6.17 | 1.25 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.42 | |
| 10.91 | 11.33 | 8.46 | 7.03 | 8.67 | 10.92 | 13.45 | 12.81 | 14.92 | 11.83 | 13.71 | 11.78 | |
| Total Liabilities | 41.52 | 41.40 | 46.43 | 44.53 | 43.63 | 41.41 | 46.96 | 49.28 | 54.16 | 52.42 | 55.73 | 55.87 |
| 8.36 | 7.81 | 17.49 | 17.57 | 17.04 | 16.60 | 16.17 | 16.00 | 16.62 | 17.88 | 18.15 | 18.13 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.48 | 0.42 | 0.00 | 0.00 | 0.06 |
| Investments | 0.70 | 0.73 | 0.99 | 1.12 | 1.13 | 0.82 | 0.24 | 9.11 | 9.66 | 10.43 | 11.22 | 12.30 |
| 32.46 | 32.86 | 27.95 | 25.84 | 25.46 | 23.99 | 30.55 | 23.69 | 27.46 | 24.11 | 26.36 | 25.38 | |
| Total Assets | 41.52 | 41.40 | 46.43 | 44.53 | 43.63 | 41.41 | 46.96 | 49.28 | 54.16 | 52.42 | 55.73 | 55.87 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.75 | -1.43 | 4.91 | 1.23 | 3.74 | 6.20 | 7.59 | 0.95 | 0.22 | 0.76 | 0.95 | 6.12 | |
| -0.18 | 0.05 | -0.59 | -0.62 | -0.10 | -0.37 | -5.58 | -5.47 | 0.53 | -1.31 | -0.18 | -0.57 | |
| -1.90 | -2.06 | -2.33 | -1.89 | -4.26 | -5.36 | 1.30 | 0.93 | 0.58 | -0.72 | -0.46 | -0.94 | |
| Net Cash Flow | 2.67 | -3.44 | 1.99 | -1.28 | -0.62 | 0.48 | 3.31 | -3.59 | 1.33 | -1.27 | 0.31 | 4.60 |
| Free Cash Flow | 4.43 | -1.58 | 4.30 | 0.60 | 3.63 | 6.09 | 7.46 | 0.11 | -0.85 | -0.67 | 0.01 | 5.40 |
| CFO/OP | 201% | -42% | 195% | 63% | 194% | 437% | 373% | 64% | 37% | 55% | 55% | 229% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 62.73 | 67.16 | 54.13 | 49.81 | 35.45 | 35.32 | 33.23 | 22.23 | 26.75 | 26.42 | 25.86 | 28.24 |
| Inventory Days | 210.09 | 206.51 | 152.04 | 146.77 | 191.00 | 208.65 | 117.86 | 115.06 | 167.70 | 137.28 | 160.90 | 121.05 |
| Days Payable | 103.39 | 100.86 | 58.22 | 38.75 | 60.93 | 83.69 | 70.57 | 69.63 | 98.30 | 46.96 | 51.05 | 51.68 |
| Cash Conversion Cycle | 169.43 | 172.82 | 147.94 | 157.84 | 165.52 | 160.28 | 80.52 | 67.67 | 96.15 | 116.75 | 135.70 | 97.61 |
| Working Capital Days | 68.47 | 104.73 | 60.69 | 30.16 | 40.10 | 72.06 | 39.51 | 42.41 | 52.33 | 56.75 | 62.80 | 41.96 |
| ROCE % | 6.80% | 7.75% | 4.26% | 5.14% | 5.58% | 4.13% | 5.59% | 6.94% | 6.08% | 5.36% | 5.47% | 6.41% |
Insights
In beta| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Electricity Purchased Units |
|
|||||||||||
| Fuel Consumed - Diesel Liters |
||||||||||||
| Median Remuneration of Employees INR |
||||||||||||
| Number of Permanent Employees Count |
||||||||||||
| Fuel Consumed - LSHS kg |
||||||||||||
Extracted by Screener AI
Documents
Announcements
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
1d - Filed annual secretarial compliance report for year ended 31 March 2026; no additional non-compliances reported.
-
Announcement Under Regulation 30-Update Demand Order From Office Of Assistant Commissioner, Jurisdiction Sector 3 (Mobile Squad-1) Shamli State/UT, Uttar Pradesh For Detention Of Conveyance & Goods Due To Discrepancy In Quantity As Per Invoice & Quantity As Per Physical Verification Of Goods.
7 May - GST detention order for goods discrepancy; Rs.31,699 penalty paid, proceedings dropped on 06/05/2026.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
7 May - Newspaper Publication for Audited Financials for the Q and Year ended 31.03.2026
-
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
5 May - Company confirms it is not a large corporate under SEBI debt disclosure norms for FY2026.
-
Statement Of Deviation And Variation Of Funds For Q Ended 31.03.2026
5 May - Filed Q4 FY26 statement of no deviation for preferential issue proceeds; funds remain in escrow FD.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
SPL is engaged in the business of manufacturing and trading of Ayurveda based medicines under the brand name SANDU